Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Leases: 2023-2024

Historic Current Leases for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $12.9 million.

  • Iovance Biotherapeutics' Current Leases was N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2024, which is 65.82% up from last year.
  • Iovance Biotherapeutics' Current Leases amounted to $12.9 million in FY2024, which was up 65.82% from $7.8 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Current Leases ranged from a high of $12.9 million in FY2024 and a low of $7.8 million during FY2023.
  • Over the past 2 years, Iovance Biotherapeutics' median Current Leases value was $10.3 million (recorded in 2023), while the average stood at $10.3 million.
  • Data for Iovance Biotherapeutics' Current Leases shows a peak YoY spiked of 65.82% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Iovance Biotherapeutics' Current Leases stood at $7.8 million in 2023, then spiked by 65.82% to $12.9 million in 2024.